Speckman R A, Garg A, Du F, Bennett L, Veile R, Arioglu E, Taylor S I, Lovett M, Bowcock A M
Division of Human Genetics, Departments of Genetics and Pediatrics, Washington University School of Medicine, St. Louis, MO, USA.
Am J Hum Genet. 2000 Apr;66(4):1192-8. doi: 10.1086/302836.
Familial partial lipodystrophy (FPLD), Dunnigan variety, is an autosomal dominant disorder characterized by marked loss of subcutaneous adipose tissue from the extremities and trunk but by excess fat deposition in the head and neck. The disease is frequently associated with profound insulin resistance, dyslipidemia, and diabetes. We have localized a gene for FPLD to chromosome 1q21-q23, and it has recently been proposed that nuclear lamin A/C is altered in FPLD, on the basis of a novel missense mutation (R482Q) in five Canadian probands. This gene had previously been shown to be altered in autosomal dominant Emery-Dreifuss muscular dystrophy (EDMD-AD) and in dilated cardiomyopathy and conduction-system disease. We examined 15 families with FPLD for mutations in lamin A/C. Five families harbored the R482Q alteration that segregated with the disease phenotype. Seven families harbored an R482W alteration, and one family harbored a G465D alteration. All these mutations lie within exon 8 of the lamin A/C gene-an exon that has also been shown to harbor different missense mutations that are responsible for EDMD-AD. Mutations could not be detected in lamin A/C in one FPLD family in which there was linkage to chromosome 1q21-q23. One family with atypical FPLD harbored an R582H alteration in exon 11 of lamin A. This exon does not comprise part of the lamin C coding region. All mutations in FPLD affect the globular C-terminal domain of the lamin A/C protein. In contrast, mutations responsible for dilated cardiomyopathy and conduction-system disease are observed in the rod domain of the protein. The FPLD mutations R482Q and R482W occurred on different haplotypes, indicating that they are likely to have arisen more than once.
家族性部分脂肪营养不良(FPLD),邓尼根型,是一种常染色体显性疾病,其特征为四肢和躯干的皮下脂肪组织显著减少,而头颈部脂肪过度沉积。该疾病常伴有严重的胰岛素抵抗、血脂异常和糖尿病。我们已将FPLD的一个基因定位于染色体1q21 - q23,最近有人提出,基于5名加拿大先证者中的一个新的错义突变(R482Q),FPLD中核纤层蛋白A/C发生了改变。此前已证明该基因在常染色体显性遗传性埃默里 - 德赖富斯肌营养不良(EDMD - AD)、扩张型心肌病和传导系统疾病中发生改变。我们检测了15个FPLD家族的核纤层蛋白A/C突变情况。5个家族存在与疾病表型共分离的R482Q改变。7个家族存在R482W改变,1个家族存在G465D改变。所有这些突变都位于核纤层蛋白A/C基因的第8外显子内,该外显子也已被证明存在导致EDMD - AD的不同错义突变。在一个与染色体1q21 - q23连锁的FPLD家族中未检测到核纤层蛋白A/C的突变。一个非典型FPLD家族在核纤层蛋白A的第11外显子存在R582H改变。该外显子不包含核纤层蛋白C编码区域的一部分。FPLD中的所有突变均影响核纤层蛋白A/C蛋白的球状C末端结构域。相比之下,导致扩张型心肌病和传导系统疾病的突变则出现在该蛋白的杆状结构域。FPLD突变R482Q和R482W出现在不同的单倍型上,表明它们可能不止一次出现。